Immunotherapy of Cervical Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (15 May 2022) | Viewed by 5298
Special Issue Editor
Interests: Immunology of cervical cancer; squamous cell carcinoma (SCC); uterine cervical neoplasm; human papillomavirus (HPV); trachelectomy; cisplatin-based concurrent radiochemotherapy (CCRT); adoptive cell therapy; tumor infiltrating lymphocyte (TIL)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cervical cancer causes 528,000 new cases and 266,000 deaths worldwide every year, more than any other gynecological tumor, and is the fourth most common malignancy diagnosed in women. Although human papillomavirus (HPV) vaccines and cancer screenings have effectively decreased cervical cancer mortality in recent years, there is also an increasing demand for new therapeutic approaches to incurable metastatic cervical cancer, which cannot be treated with surgery or radiation.
Cervical cancer is closely linked to the persistent infection of carcinogenic HPV, which express viral oncogenes, causing the enhancement of genomic instability, accumulation of somatic mutations accumulation, then trigger immune system defects in cancer progress. Among these carcinogenic HPV types, the association with tumor risk and histological subtypes varies substantially, but the reasons for these differences remain elusive. Besides, therapeutic approaches for HPV-negative gastric type cervical cancer are needed in Asian countries.
A comprehensive understanding of tumor immunology has a certain promoting effect on the treatment of cervical cancer. Immune therapy including, but not limited to, the immune checkpoint blockade (ICB), adoptive cell transfer, therapeutic vaccines and cytokine treatment, has become a promising breakthrough in cancer treatment. This Special Issue will highlight the current state of tumor immunity in cervical cancer in all its diversity, covering both basic and (pre-)clinical aspects, advancing our knowledge to improve cervical cancer treatment.
Dr. Takashi Iwata
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cervical cancer
- oncogenesis
- immune therapy
- human papillomavirus (HPV)
- immune checkpoint inhibitor (ICI)
- adoptive cell therapy (ACT)
- therapeutic vaccines
